Incyte
Prezzo: 108.53Società e modello di business
Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for oncology and other serious diseases. Its core products include Jakafi, a treatment for certain blood disorders, and other investigational therapies targeting various cancers. The company generates revenue mainly from product sales and collaborations with other pharmaceutical firms.
Profilo di investimento
The investment profile of Incyte is more aligned with growth investors, given its focus on innovative therapies and potential for future revenue increases. However, the current market conditions and performance metrics suggest a cautious approach. The stock may appeal to those with a medium to long investment horizon, prioritizing potential capital appreciation over immediate income. Liquidity is moderate, suitable for investors with basic to advanced experience.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- 7.30 OK
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- -15.5% ↓
- Sorpresa EPS
- 31.2% meglio del previsto
- Volatilità 20g
- 2.1% stabile
Impatto della previsione
positivoTraccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-06-05 02:40 | Vendi | Compra | Mixed signals; revenue decline raises caution. |
| 2026-06-03 02:43 | Mantieni | Vendi | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-05-24 02:42 | Vendi | Mantieni | Weak fundamentals and mixed momentum signal caution. |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-06-10 11:11 | H.C. Wainwright | Target alzato | — → 140 | 103.23 |
| 2026-06-09 13:11 | Stifel Nicolaus | Aggiorna | — → 123 | 103.07 |
| 2026-06-08 18:53 | Oppenheimer | Target alzato | 90 → 107 | 100.64 |
Ancora nulla